There is a conversation I have had more than once with people who are, by most measures, financially sophisticated. They own diversified portfolios. They understand the mechanics of compound interest. They think seriously about risk.

And yet, when the conversation turns to health, the framing shifts almost immediately.

Health becomes a cost. Something to budget for when necessary, optimize when convenient, and otherwise leave to the background. A lifestyle concern rather than a capital allocation decision.

I used to think this way too. Then I noticed the error.

Warren Buffett has a thought experiment he returns to often.

Imagine a genie appears when you are sixteen years old and offers you any car you want. The catch: it is the only car you will ever own. Whatever you choose today must last a lifetime — no replacements, no upgrades, no second chances.

How would you treat that car?

You would read the manual carefully. You would service it before it needed servicing. You would address every small problem before it became a structural one. You would never let a minor issue compound into something irreversible.

Buffett uses this parable to describe your mind and body.

You receive one. It must last the entire journey. And unlike the car in the story, there is no genie and no hypothetical — the terms of the arrangement are simply the terms of being alive.

Most people do not treat their bodies this way. They treat them reactively. Something hurts, they address it. Something breaks, they fix it. In the intervals between problems, they assume everything is fine.

This is, in financial terms, the equivalent of only reviewing your portfolio after a crash.

Here is what makes health genuinely unusual as an asset class: its returns are almost entirely invisible while they are accumulating.

The investor who diversifies a portfolio rarely knows which specific decision prevented which specific loss. The person who exercises consistently throughout their forties does not receive a statement showing which cardiovascular events were avoided, which cognitive decline was deferred, which years were preserved. The protection is real. The evidence of it is structurally hidden.

This is not a bug in the system. It is the mechanism.

Prevention does not announce itself. It simply does not become the emergency you never had.

The difficulty is that invisible returns are psychologically hard to act on. We respond to problems. We are less naturally equipped to invest in the absence of problems. This is why so many intelligent people, who would never ignore a deteriorating position in their financial portfolio, will casually ignore deteriorating metabolic indicators for years at a time.

The risk compounds quietly. Then it does not.

The financial case for health is more direct than most people realize.

Compound interest requires time. That is its only true input. Given sufficient time, even modest returns produce extraordinary outcomes. Given insufficient time — because of illness, reduced capacity, or early exit from productive life — even excellent returns produce modest ones.

This means that every year of productive health is not merely valuable in itself. It is a multiplier on every other financial decision you have made.

Consider two investors with identical portfolios and identical annual returns. One remains in full productive health until 80. The other experiences serious metabolic illness in their early sixties, drawing down capital to fund care and exiting the compounding period twenty years early. The difference in final outcomes is not incremental. It is transformational — measured in multiples, not percentages.

Health does not just add years to the curve. It protects the steepest part of the curve, the phase where compounding finally becomes visible and dramatic. Losing those years is not a health outcome. It is a financial outcome.

There is a concept in longevity medicine called the healthspan gap — the distance between how long a person lives and how long they live well.

Research published in recent years suggests this gap averages somewhere between nine and ten years. Meaning the typical person spends roughly a decade at the end of their life in a state of meaningfully reduced function: chronic illness, limited mobility, cognitive decline, dependence.

This is the period during which capital is consumed rather than compounded. The period during which the decisions of decades earlier are settled, finally and irrevocably.

Most financial planning treats this as an afterthought. A line item for care costs. An actuarial variable.

I think it deserves to be treated as a design problem.

The question is not only how long will I live but how long will I be capable. Capable of working, thinking, traveling, deciding, investing. Capable of using what I have spent decades building.

A portfolio that runs out of time before it runs out of money is still a failure — just a different kind.

The most useful framework I have encountered for thinking about this practically comes from longevity medicine: the idea of reverse-engineering your physical capacity from the future backward.

The exercise is simple. Identify the things you want to be able to do at eighty. Not extraordinary things. Ordinary ones. Carry a bag through an airport. Walk up three flights of stairs without losing breath. Get up from the floor without assistance. Lift a grandchild.

These sound trivial at forty. They are not trivial to achieve at eighty. They require a specific and substantial physical foundation — cardiovascular capacity, muscle mass, mobility, bone density — that takes decades to build and cannot be rapidly acquired once lost.

The insight is that if you want to be able to do these things at eighty, you need to be doing significantly more than these things at forty. The margin for degradation must be built in advance, while the biological materials are available to build it.

This is compounding logic applied to physiology. The earlier you invest, the more buffer you accumulate. The more buffer you have, the less catastrophic the inevitable losses of aging become.

An eighty-year-old with the cardiovascular baseline of a fit sixty-year-old will experience the losses of aging very differently from one who arrives at eighty already depleted. The same years, lived in radically different conditions.

None of this requires elaborate protocols or expensive interventions.

The research on what actually drives long-term biological health is, at its core, unglamorous. Consistent moderate-intensity cardiovascular exercise — the kind that is sustainable, not punishing. Resistance training twice a week to protect muscle mass through the decades when it naturally declines. Eight to nine hours of sleep, taken seriously rather than optimized around. A diet that is more whole food than not.

These are not new ideas. Their compounding value lies precisely in their ordinariness — the fact that they can be maintained without drama, year after year, accumulating quietly in the background.

The interesting addition, and the one I have found most useful personally, is diagnostic clarity. Annual blood work that goes beyond standard panels. Understanding your own metabolic baseline — including markers that predict cardiovascular risk decades in advance rather than confirming disease after it has already developed.

Most people have no idea where they actually stand metabolically. They know their weight. They know if they feel well or unwell. But the early warnings that matter most are invisible without measurement, which means they compound undetected.

Measurement is, in this sense, the same discipline as portfolio monitoring. You cannot manage what you cannot see.

Your financial portfolio grows during the years when your body allows it to.

Protecting one without managing the other is not a strategy. It is half a plan.

The highest-returning investment is the one that keeps all your other investments in play.

In ten years, will this daily habit have protected or eroded your capacity to use everything you are building?

I recently completed a more comprehensive blood panel than I had previously bothered with — one that included ApoB, fasting insulin, and inflammatory markers alongside the standard checks. The results were largely fine. But largely fine revealed two things worth paying attention to, which a standard annual physical would not have flagged.

I am also tracking my resting heart rate over time, not because any single measurement matters, but because the trend line over months is genuinely informative. These are small investments in visibility. I think of them the same way I think about reviewing a portfolio: not to react, but to stay oriented.

Sleep is the area I have most recently started treating as non-negotiable rather than aspirational. I aim for at least eight hours every night, and I keep a consistent schedule — up at six, asleep by ten. The schedule matters more than I expected. Consistency seems to do more for how I feel than the total number alone.

On the training side, I do Pilates three times a week, alongside light resistance work to keep building the muscle mass that becomes harder to maintain with each passing decade. Neither is dramatic. Both are sustainable, which is the point.

I currently take a small, deliberate stack of supplements — omega-3, vitamin D, and magnesium citrate — and I am weighing whether to switch the magnesium to a glycinate form, which some evidence suggests absorbs better and supports sleep more directly. Nothing urgent. Just the kind of incremental refinement that, over years, is the whole exercise.

Annual comprehensive blood panel, with ApoB

Most standard health checks measure LDL cholesterol. ApoB — apolipoprotein B — measures something more precise: the number of atherogenic particles in the bloodstream. It is a more accurate predictor of long-term cardiovascular risk, particularly in people who otherwise appear metabolically healthy.

Cardiovascular disease remains the leading cause of death in most developed countries. It is also among the most preventable, when identified early. The gap between early identification and late identification can be measured in decades of productive life.

Getting a baseline ApoB measurement, and tracking it over time, costs very little. The information it provides is structural, not symptomatic — it tells you something about what is building quietly rather than what has already arrived.

That is, almost exactly, what compounding looks like.

See you next Tuesday.